Sumitomo Pharma Co.

4506.TSE

12.17 USD

-0.09

-0.73%

Overview

Last close

12.17 usd

Market cap

5.46B usd

52 week high

20.84 usd

52 week low

5.19 usd

Target price

14.12 usd

Valuation

P/E

18.3936

Forward P/E

20.202

Price/Sales

1.7651

Price/Book Value

2.1019

Enterprise Value

5.89B usd

EV/Revenue

2.0541

EV/EBITDA

8.4812

Key financials

Revenue TTM

3.10B usd

Gross Profit TTM

1.65B usd

EBITDA TTM

104.83M usd

Earnings per Share

0.66 usd

Dividend

N/A usd

Total assets

5.42B usd

Net debt

394.43M usd

About

Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.